4.7 Article

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Africa: Current Considerations and Future Projections

Related references

Note: Only part of the references are listed.
Article Medicine, General & Internal

SARS-CoV-2 exposure in Malawian blood donors: an analysis of seroprevalence and variant dynamics between January 2020 and July 2021

Jonathan Mandolo et al.

Summary: The study found that Malawi experienced two waves of SARS-CoV-2 epidemic, with widespread exposure and high antibody detection rates in both urban and rural areas. The first wave sera showed higher neutralization activity against the original variant, while the second wave sera exhibited higher neutralization activity against the Beta variant. Blantyre and Mzuzu also showed signs of a third pandemic wave.

BMC MEDICINE (2021)

Article Public, Environmental & Occupational Health

Seroprevalence of ancestral and Beta SARS-CoV-2 antibodies in Malagasy blood donors

Solohery Lalaina Razafimahatratra et al.

Lancet Global Health (2021)

Article Medicine, General & Internal

SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN)

Victoria Jane Hall et al.

Summary: This study investigated whether antibodies against SARS-CoV-2 were associated with a decreased risk of symptomatic and asymptomatic reinfection. It found that individuals with a previous history of SARS-CoV-2 infection had an 84% lower risk of reinfection, with a median protective effect lasting for 7 months following primary infection.

LANCET (2021)

Article Biochemistry & Molecular Biology

Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2

Joseph E. Ebinger et al.

Summary: Virus-specific antibody levels after a single dose of the BNT162b2 vaccine in individuals previously infected with SARS-CoV-2 are similar to levels after two doses of the vaccine in infection-naive individuals. Post-vaccine symptoms were more prominent for those with prior infection after the first dose, but symptomology was similar between groups after the second dose.

NATURE MEDICINE (2021)

Article Medicine, General & Internal

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

S. A. Madhi et al.

Summary: The ChAdOx1 nCoV-19 vaccine did not provide significant protection against mild-to-moderate Covid-19 caused by the B.1.351 variant, with an efficacy of 10.4%. The incidence of serious adverse events was balanced between the vaccine and placebo groups.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Article Medicine, General & Internal

Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant

V. Shinde et al.

Summary: The NVX-CoV2373 vaccine showed efficacy in preventing Covid-19, with higher vaccine efficacy observed among HIV-negative participants. Most infections were caused by the B.1.351 variant.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Article Multidisciplinary Sciences

mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection

Leonidas Stamatatos et al.

Summary: The study found that vaccination of both previously infected individuals and those who were not infected resulted in increased neutralizing antibody titers, with previously infected individuals showing a greater boost in neutralizing titers. Vaccination of naive individuals also elicited cross-neutralizing responses, but at lower titers.

SCIENCE (2021)

Article Psychology, Biological

A global database of COVID-19 vaccinations

Edouard Mathieu et al.

Summary: An effective rollout of COVID-19 vaccines is crucial in ending the pandemic, and Our World in Data's vaccination dataset tracks the progress and scale of vaccine distribution globally, aiding policymakers and researchers in understanding the global vaccination efforts.

NATURE HUMAN BEHAVIOUR (2021)

Article Multidisciplinary Sciences

Distinct clinical and immunological profiles of patients with evidence of SARS-CoV-2 infection in sub-Saharan Africa

Ben Morton et al.

Summary: This study characterized clinical and immunological responses of patients with confirmed and suspected COVID-19 in a hospital in Malawi, revealing that suspected patients had inflammatory profiles similar to confirmed cases, potentially making them a target population for COVID-19 treatment strategies.

NATURE COMMUNICATIONS (2021)

Letter Medicine, General & Internal

ChAdOx1 nCoV-19 Vaccine Efficacy against the B.1.351 Variant

Frank Struyf et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Article Medicine, General & Internal

SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy

Laith J. Abu-Raddad et al.

Summary: The study shows that reinfection is rare in Qatar's young and international population, with natural infection providing strong protection against reinfection with an estimated efficacy of around 95% for at least seven months. Reinfections are often less severe than primary infections.

ECLINICALMEDICINE (2021)

Article Multidisciplinary Sciences

Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors

Sophie Uyoga et al.

Summary: The prevalence of anti-SARS-CoV-2 immunoglobulin G among blood donors in Kenya from April to June 2020 was 4.3%, with the highest rates in urban counties like Mombasa, Nairobi, and Kisumu. This suggests that SARS-CoV-2 exposure is more widespread than case-based surveillance indicates.

SCIENCE (2021)

Article Public, Environmental & Occupational Health

Vaccinology in sub-Saharan Africa

Jennifer Moisi et al.

BMJ GLOBAL HEALTH (2019)

Article Immunology

2009 Pandemic Influenza A Virus Subtype H1N1 Vaccination in Africa-Successes and Challenges

Richard Mihigo et al.

JOURNAL OF INFECTIOUS DISEASES (2012)